Want to see FBRX full AI Analyst Report?
FBRX Stock Chart & Stats
$54.78
-$4.92(-8.24%)
At close: 4:00 PM EDT
$54.78
-$4.92(-8.24%)
Day’s Range― - ―
52-Week Range$9.10 - $77.20
Previous CloseN/A
Volume575.89K
Average Volume (3M)97.46K
Market Cap
$1.57B
Enterprise Value$403.77
Total Cash (Recent Filing)$58.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 17, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.58
Shares Outstanding20,478,817
10 Day Avg. Volume83,173
30 Day Avg. Volume97,456
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)65.81
Price to Sales (P/S)0.00
P/FCF Ratio-78.70
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$74.00Price Target Upside35.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Definitive Acquisition AgreementA signed all-cash acquisition materially de-risks Forte’s development and funding pathway: it secures value realization for shareholders, removes standalone financing needs, and accelerates integration of Forte’s assets into a larger commercial organization, a lasting structural change.
Positive Phase 1b FB102 Vitiligo DataRobust Phase 1b proof-of-concept provides durable scientific validation for FB102, improving the asset’s de-risking profile, bolstering strategic partnership potential, and underpinning acquisition interest and future development prioritization within immunology franchises.
Debt-free Balance SheetHaving no debt materially reduces financial fragility and interest burden, preserving strategic optionality. For a clinical-stage biotech, this increases attractiveness to partners or acquirers and reduces execution risk tied to leverage during costly development phases.
Bears Say
No Reported RevenueAbsence of operating revenue means the company cannot self-fund development and remains dependent on external capital or corporate transactions; this structural reliance elevates execution risk and limits long-term financial independence.
Deep Negative Cash Flow And BurnSustained negative operating and free cash flow indicate persistent cash consumption from R&D and operations. Over months this necessitates frequent financing or strategic exits, increasing dilution risk and constraining investment flexibility for pipeline advancement.
Shrinking Equity And AssetsDeclining equity and asset bases weaken the balance sheet buffer against adverse outcomes, limit borrowing or transaction optionality, and reflect that prior funding is being consumed. This reduces resilience if development timelines extend or unexpected costs arise.
Forte Biosciences News
FBRX FAQ
What was Forte Biosciences Inc.’s price range in the past 12 months?
Forte Biosciences Inc. lowest stock price was $9.10 and its highest was $77.20 in the past 12 months.
What is Forte Biosciences Inc.’s market cap?
Forte Biosciences Inc.’s market cap is $1.57B.
When is Forte Biosciences Inc.’s upcoming earnings report date?
Forte Biosciences Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 15 days.
How were Forte Biosciences Inc.’s earnings last quarter?
Forte Biosciences Inc. released its earnings results on May 11, 2026. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Forte Biosciences Inc. overvalued?
According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued.
Does Forte Biosciences Inc. pay dividends?
Forte Biosciences Inc. does not currently pay dividends.
What is Forte Biosciences Inc.’s EPS estimate?
Forte Biosciences Inc.’s EPS estimate is -0.88.
How many shares outstanding does Forte Biosciences Inc. have?
Forte Biosciences Inc. has 20,478,817 shares outstanding.
What happened to Forte Biosciences Inc.’s price movement after its last earnings report?
Forte Biosciences Inc. reported an EPS of -$1.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.243%.
Which hedge fund is a major shareholder of Forte Biosciences Inc.?
Currently, no hedge funds are holding shares in FBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Forte Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$74.00 (35.09% Upside)
$74.00 (35.09% Upside)
Blogger Sentiment
Neutral
FBRX Sentiment 56%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.64%
Trailing 12-Months
Company Description
Forte Biosciences Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
FBRX Stock 12 Month Forecast
Average Price Target
$74.00
▲(35.09% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protalix
―
Protara Therapeutics
―
Innate Pharma
―
Ownership Overview
1.83% Insiders
20.69% Mutual Funds
0.04% Other Institutional Investors
67.70% Public Companies and
Individual Investors